Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736349 | 0.87 | PIK3CD (0.37) | PIK3CD | |
| SCHEMBL7940771 | 0.84 | PIK3CD (0.36) | PIK3CD | |
| SCHEMBL12205827 | 0.80 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL18997704 | 0.78 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL2736351 | 0.76 | ALDH1A1 (0.33) | PIK3CD | |
| SCHEMBL12408143 | 0.76 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL14350219 | 0.76 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL15471309 | 0.73 | MEN1 (0.35) | — | |
| SCHEMBL19363802 | 0.73 | PIK3CD (0.47) | PIK3CD | |
| SCHEMBL14350139 | 0.73 | SLC6A2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2023-02-09 | — | — | US | disclosed |
| US-11208388-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20200172495-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-06-04 | — | — | US | disclosed |
| US-10544106-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10172868-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180125855-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9550770-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | PIK3CD 27/4885 |
| US-10544106-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | PIK3CD 27/4885 |
| US-10172868-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | PIK3CD 237/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | PIK3CD 27/4885 |
| US-20180125855-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | PIK3CD 237/4885 |
| US-11208388-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | PIK3CD 27/4885 |
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | PIK3CD 27/4885 |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | PIK3CD 27/4885 |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CDK2, MAP3K6, MAP3K2 | PIK3CD 73/4885 |
| US-20200172495-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | PIK3CD 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.